Aclarion (NASDAQ:ACON) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aclarion (NASDAQ:ACON) to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Aclarion Price Performance

Shares of ACON opened at $4.94 on Friday. The stock has a market capitalization of $3.31 million, a PE ratio of -0.33 and a beta of 1.43. The business’s fifty day moving average price is $6.62 and its 200 day moving average price is $7.22. Aclarion has a 12-month low of $4.80 and a 12-month high of $3,499.51.

Aclarion (NASDAQ:ACON) last issued its earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29). Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%.The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. As a group, research analysts anticipate that Aclarion will post -263.33 earnings per share for the current fiscal year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.